H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $93 and keeps a Buy rating on the shares. The firm says Cortrophin Gel script data continues to track ahead of its forecasts. In addition, the the addressable market for Cortrophin is larger larger previously modeled, with 500,000 acute gout flares offering a “very significant opportunity, along with multiple other indications,” the analyst tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.